Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, The Fly reports.

Several other analysts also recently commented on the stock. Credit Suisse Group set a $39.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Vetr upgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 target price on the stock in a report on Monday, July 24th. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a report on Monday, July 17th. Finally, BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a report on Tuesday, August 8th. Three research analysts have rated the stock with a sell rating, twenty have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $37.69.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at 17.97 on Wednesday. Teva Pharmaceutical Industries Limited has a 12-month low of $16.81 and a 12-month high of $53.96. The firm’s market cap is $18.26 billion. The stock’s 50 day moving average is $28.78 and its 200-day moving average is $31.30.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. The firm had revenue of $5.69 billion during the quarter, compared to analyst estimates of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business’s revenue was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.25 earnings per share. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Cut to “Neutral” at Citigroup Inc.” was published by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-cut-to-neutral-at-citigroup-inc/1494035.html.

A number of institutional investors have recently added to or reduced their stakes in TEVA. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries Limited during the second quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. boosted its position in Teva Pharmaceutical Industries Limited by 7.8% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the period. Kistler Tiffany Companies LLC boosted its position in Teva Pharmaceutical Industries Limited by 74.7% in the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the period. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited during the first quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. boosted its position in Teva Pharmaceutical Industries Limited by 2.6% in the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. 56.04% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

The Fly

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.